ArticleDermatology and therapy2026
HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHS-20137 is a novel interleukin-23 inhibitor and is suggested to be effective for the treatment of psoriasis in a phase 1b study. Our study aimed to evaluate the efficacy and safety of HS-20137 in patients with moderate-to-severe plaque psoriasis in a larger and longer phase 2 study.
methodsThis was a randomized, double-blind, placebo-controlled phase 2 study up to 52 weeks. The study was conducted from September 2023 to February 2025 at 22 sites across mainland China and enrolled male and female adults with moderate-to-severe psoriasis. Dosing was scheduled at weeks 0 and 4, and subsequently every 8 weeks (Q8W) or Q12W. Eligible patients were randomized 1:1:1:1 to subcutaneously receive HS-20137 at doses of 100 mg Q8W, 200 mg Q8W, 200 mg Q12W, or placebo. Patients switched to receive HS-20137 200 mg Q8W at week 16 or week 28. The primary endpoint was the percentage of patients achieving at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 16.
resultsIn total, 159 participants were enrolled, with a mean (SD) PASI score of 25.8 (10.9). More patients treated with HS-20137 achieved PASI 90 compared to placebo (65.0%-76.9% in HS-20137 groups vs. 7.5% in placebo group, P < 0.001) at week 16, as well as PASI 100, investigator global assessment (IGA) score of 0/1, and IGA 0. The PASI score significantly decreased in all treatment groups (41.4%-46.2%) after the first injection by week 4 and was maintained through week 52. During the placebo-controlled period, treatment-emergent adverse event (TEAE) rates were similar among groups (77.5%-67.5%). Throughout the study, most TEAEs were mild; only one serious treatment-related AE occurred, and it resolved after treatment.
conclusionsHS-20137 treatment was tolerable and effective in patients with psoriasis, supporting further investigation and development.
trial registrationChiCTR2300075645.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.